Korro Bio is a company that is pioneering RNA editing to deliver the future of medicine. The company's proprietary platform, OPERA (Oligonucleotide Promoted Editing of RNA), harnesses the natural base editing system of the body, specifically ADAR (Adenosine Deaminase Acting on RNA), to make precise, single-base edits to RNA. Korro Bio was launched to turn scientific insights into life-altering new treatments for patients.
Its platform, OPERA, has been designed to address several challenges that are facing current gene therapy and gene editing approaches, including safety and flexibility of delivery mechanisms.
Korro Bio is prioritizing therapeutic indications across tissues where safe and targeted editing of messenger RNA could provide unique benefits over other modalities in development.